Q2 2025 saw a reversal of many first quarter factor trends as the general malaise surrounding US tariff policy impact seemed to moderate, the global tech rally resumed, and equities were up broadly.

Andexanet alfa (Andexxa; AstraZeneca), compared with usual care, improves hemostasis in patients who have an intracranial bleed while taking a factor Xa inhibitor, according to top-line results of ...

Please provide your email address to receive an email when new articles are posted on . AIMS65 score predicted mortality and rebleeding for patients on anticoagulants with gastrointestinal bleeding.

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...

FormFactor (FORM) has been on a downward spiral lately with significant selling pressure. After declining 31.9% over the past four weeks, the stock looks well positioned for a trend reversal as it is ...